Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
|Articles|April 15, 2022
News Roundup: April 11 to April 15
Author(s)Lauren Biscaldi, MS
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
Creating A Successful Social Media Presence
Social media is a great way to gain exposure, but there are many dos-and-don’ts to understand when signing up for a social platform.
Expert Interview: Update on Pediatric Vaccines for COVID-19, RSV
William J. Muller, MD, PhD, discusses COVID-19 vaccinations for children and what is on the horizon for a potential RSV vaccine.
COVID-19 Vaccine: FDA Approval Did Not Increase Public Vaccine Acceptance
Respondents to a recent poll were still hesitant to get the Pfizer-BioNTech shot.
Transform With American Associated Pharmacies at the 2022 Annual Conference
The theme of this year's AAP conference is transformation.
Tapentadol Vs Oxycodone Evaluated for Postoperative Gastrointestinal Adverse Drug Events
Postoperative pain can require opioids, which may lead to opioid-induced constipation.
Advertisement
Related to this article
Cohort studies found no clear cardiovascular benefit from PPV23 vaccination, leaving its role in cardiovascular prevention unresolved.
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.
Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
2
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
3
Generic Drug Costs Burdening Patients as Much as Brand Name Options
4
Social Media Best Practices for Pharmacists: Why Visibility Matters
5